Pacira BioSciences, Inc. (PCRX)
Days of sales outstanding (DSO)
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Receivables turnover | — | — | — | — | — | |
DSO | days | — | — | — | — | — |
December 31, 2024 calculation
DSO = 365 ÷ Receivables turnover
= 365 ÷ —
= —
The days of sales outstanding (DSO) ratio for Pacira BioSciences, Inc. remained consistent at an average of "N/A days" from December 31, 2020, to December 31, 2024. The stable DSO indicates that the company effectively manages its accounts receivable process, with minimal delays in collecting payments from customers. This stability suggests efficient credit policies and effective collection practices, which are positive indicators of the company's financial health and operational effectiveness.
Peer comparison
Dec 31, 2024
Company name
Symbol
DSO
Pacira BioSciences, Inc.
PCRX
—
Abbott Laboratories
ABT
—
AbbVie Inc
ABBV
—
ACADIA Pharmaceuticals Inc
ACAD
—
Alkermes Plc
ALKS
90.15
Amphastar P
AMPH
67.96
ANI Pharmaceuticals Inc
ANIP
—
Arcus Biosciences Inc
RCUS
7.07
Biomarin Pharmaceutical Inc
BMRN
84.73
Bristol-Myers Squibb Company
BMY
81.21
Catalyst Pharmaceuticals Inc
CPRX
—